Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Novo Nordisk(NVO) The Motley Fool·2025-04-23 09:50Denmark-based pharmaceutical giant Novo Nordisk (NVO 2.66%) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as good as investors expected. The company has also faced clinical trial setbacks: An otherwise promising weight loss medicine it developed failed to impress the market with its late-stage results.Now, Novo Nordisk is getting even more bad news, thanks to developments from its biggest competitor in the diabetes and obe ...